PubMed

Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.

Van Gaal L, Pi-Sunyer X, Després JP, McCarthy C, Scheen A.

Diabetes Care. 2008 Feb;31 Suppl 2:S229-40.PMID: 18227491 [PubMed - indexed for MEDLINE]Related articlesFree article

[Pharmacological therapy of obesity]

Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.

G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. Italian. PMID: 18773755 [PubMed - indexed for MEDLINE]Related articles

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.

Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J; RIO-North America Study Group.

JAMA. 2006 Feb 15;295(7):761-75. Erratum in: JAMA. 2006 Mar 15;295(11):1252. PMID: 16478899 [PubMed - indexed for MEDLINE]Related articlesFree article

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.

Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF; RIO-Diabetes Study Group.

Lancet. 2006 Nov 11;368(9548):1660-72. Erratum in: Lancet. 2006 Nov 11;368(9548):1650. PMID: 17098084 [PubMed - indexed for MEDLINE]Related articles

Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.

Hollander P.

Am J Med. 2007 Feb;120(2 Suppl 1):S18-28; discussion S29-32.PMID: 17296341 [PubMed - indexed for MEDLINE]Related articles

CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.

Scheen AJ.

J Neuroendocrinol. 2008 May;20 Suppl 1:139-46. Review.PMID: 18426513 [PubMed - indexed for MEDLINE]Related articles

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S; RIO-Europe Study Group.

Lancet. 2005 Apr 16-22;365(9468):1389-97. Erratum in: Lancet. 2005 Jul 30-Aug 5;366(9483):370. PMID: 15836887 [PubMed - indexed for MEDLINE]Related articles

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.

Després JP, Golay A, Sjöström L; Rimonabant in Obesity-Lipids Study Group.

N Engl J Med. 2005 Nov 17;353(20):2121-34.PMID: 16291982 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results.

Ruilope LM, Després JP, Scheen A, Pi-Sunyer X, Mancia G, Zanchetti A, Van Gaal L.

J Hypertens. 2008 Feb;26(2):357-67.PMID: 18192851 [PubMed - indexed for MEDLINE]Related articles

Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.

Van Gaal LF, Scheen AJ, Rissanen AM, Rössner S, Hanotin C, Ziegler O; RIO-Europe Study Group.

Eur Heart J. 2008 Jul;29(14):1761-71. Epub 2008 Apr 15.PMID: 18417461 [PubMed - indexed for MEDLINE]Related articlesFree article

[Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies]

Scheen AJ, Van Gaal LG, Després JP, Pi-Sunyer X, Golay A, Hanotin C.

Rev Med Suisse. 2006 Aug 23;2(76):1916-23. Review. French. PMID: 16972542 [PubMed - indexed for MEDLINE]Related articles

New approaches for the management of patients with multiple cardiometabolic risk factors.

Van Gaal LF, Peiffer F.

J Endocrinol Invest. 2006;29(3 Suppl):83-9. Review.PMID: 16751712 [PubMed - indexed for MEDLINE]Related articles

Rimonabant for overweight or obesity.

Curioni C, André C.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD006162. Review.PMID: 17054276 [PubMed - indexed for MEDLINE]Related articles

SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes.

Rosenstock J, Hollander P, Chevalier S, Iranmanesh A; SERENADE Study Group.

Diabetes Care. 2008 Nov;31(11):2169-76. Epub 2008 Aug 4.PMID: 18678611 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial.

Després JP, Ross R, Boka G, Alméras N, Lemieux I; ADAGIO-Lipids Investigators.

Arterioscler Thromb Vasc Biol. 2009 Mar;29(3):416-23. Epub 2008 Dec 26.PMID: 19112166 [PubMed - indexed for MEDLINE]Related articles

[Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes]

Scheen AJ, Van Gaal LF.

Rev Med Liege. 2007 Feb;62(2):81-5. French. PMID: 17461296 [PubMed - indexed for MEDLINE]Related articles

Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.

Nissen SE, Nicholls SJ, Wolski K, Rodés-Cabau J, Cannon CP, Deanfield JE, Després JP, Kastelein JJ, Steinhubl SR, Kapadia S, Yasin M, Ruzyllo W, Gaudin C, Job B, Hu B, Bhatt DL, Lincoff AM, Tuzcu EM; STRADIVARIUS Investigators.

JAMA. 2008 Apr 2;299(13):1547-60. Epub 2008 Apr 1.PMID: 18387931 [PubMed - indexed for MEDLINE]Related articlesFree article

Pleiotropic effects of rimonabant: clinical implications.

Després JP.

Curr Pharm Des. 2009;15(5):553-70. Review.PMID: 19199981 [PubMed - indexed for MEDLINE]Related articles

Rimonabant hydrochloride: an investigational agent for the management of cardiovascular risk factors.

Cox SL.

Drugs Today (Barc). 2005 Aug;41(8):499-508. Review.PMID: 16234873 [PubMed - indexed for MEDLINE]Related articles

Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data.

Bronander KA, Bloch MJ.

Vasc Health Risk Manag. 2007;3(2):181-90. Review.PMID: 17580728 [PubMed - indexed for MEDLINE]Related articlesFree article